Company: INMB
Filing Date: 2025-06-30
Form Type: 8-K
Source: 0001213900-25-059252
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On June 30, 2025, INmune
Bio, Inc. (the “ Company”) issued a press release announcing topline results from its Phase 2 MINDFuL trial evaluating XPro™
in patients with early Alzheimer’s disease.

The Company also made
available an updated corporate presentation, which includes additional information about the Company and its clinical programs.

Copies of the press release
and the corporate presentation are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated
herein by reference.

Item 9.01 Financial statements and Exhibits